Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies

Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.

The Importance of Re-Vaccination After Cellular Therapy
Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.
NCCN 2022 Annual Congress: Hematologic Malignancies™
The NCCN 2022 Annual Congress: Hematologic Malignancies™ will focus on updates to the NCCN Guidelines®, new, emerging and novel therapeutic agents, advances in cancer care, and the practical management of patients with hematologic malignancies, as well as re-vaccination of patients with hematologic malignancies and hematopoietic growth factors.
Emerging Treatment Landscape of Targeted Therapies in Hematologic Malignancies
It is integral for nurses to have current knowledge of new targeted therapies in hematologic malignancies to understand mechanisms of actions and side effect profiles to support optimal patient outcomes.
Recommendations for Managing Adults with Histiocytic Neoplasms: New NCCN Guidelines
That patients’ signs and symptoms are often nonspecific can lead to delays in diagnosis and treatment of histiocytic disorders, and ambiguous cases should be evaluated at centers of expertise. Although challenging, it is important that clinicians remain current with advances in the management of these disorders.
Recorded Presentations from the NCCN Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

The management of cancer is constantly evolving through the introduction of new developments related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care.

Management of Toxicities Related to CAR T-Cell Therapy

CAR T-cell therapy is associated with a novel toxicity profile with complex monitoring and supportive care requirements.

Updates in the Management of Tumor Lysis Syndrome

TLS is a potentially serious complication of anticancer therapy. If left untreated, its progression may cause acute kidney failure, cardiac arrhythmias, seizures, loss of muscle control, and death.

Prevention of Infection in Patients with Hematologic Malignancies

Nurse practitioners and other health care providers play a critical role in the recognition and management of cancer-related infections.

Pages

Subscribe to RSS - Hematologic Malignancies